Can Hasdemir1, Figen Gokcay2, Mehmet N Orman3, Umut Kocabas4, Serdar Payzin1, Hatice Sahin1, Dale R Nyholt5, Charles Antzelevitch6,7,8. 1. Department of Cardiology, Ege University School of Medicine, Izmir, Turkey. 2. Department of Neurology, Ege University School of Medicine, Izmir, Turkey. 3. Department of Biostatistics and Medical Informatics, Ege University School of Medicine, Izmir, Turkey. 4. Department of Cardiology, Baskent University Istanbul Hospital, Istanbul, Turkey. 5. School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. 6. Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA. 7. Lankenau Heart Institute, Wynnewood, Pennsylvania, USA. 8. Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Abstract
INTRODUCTION: We have previously reported high 1-year prevalence of migraine in patients with atrial arrhythmias associated with DI-type 1 BrP. The present study was designed to determine the lifetime prevalence of migraine in patients with Brugada syndrome (BrS) or drug-induced type 1 Brugada pattern (DI-type 1 BrP) and control group, to investigate the demographic and clinical characteristics, and to identify clinical variables to predict underlying BrS/DI-type 1 BrP among migraineurs. METHODS AND RESULTS: Lifetime prevalence of migraine and migraine characteristics were compared between probands with BrS/DI-type 1 BrP (n = 257) and control group (n = 370). Lifetime prevalence of migraine was 60.7% in patients with BrS/DI-type 1 BrP and 30.3% in control group (p = 3.6 × 10-14 ). On stepwise regression analysis, familial migraine (odds ratio [OR] of 4.4; 95% confidence interval [CI]: 2.0-9.8; p = 1.3 × 10-4 ), vestibular migraine (OR of 5.4; 95% CI: 1.4-21.0); p = .013), migraine with visual aura (OR of 1.8; 95% CI: 1.0-3.4); p = .04) and younger age-at-onset of migraine (OR of 0.95; 95% CI: 0.93-0.98); p = .004) were predictors of underlying BrS/DI-type 1 BrP among migraineurs. Use of anti-migraine drugs classified as "to be avoided" or "preferably avoided" in patients with BrS and several other anti-migraine drugs with potential cardiac INa /ICa channel blocking properties was present in 25.6% and 26.9% of migraineurs with BrS/DI-type 1 BrP, respectively. CONCLUSION: Migraine comorbidity is common in patients with BrS/DI-type 1 BrP. We identify several clinical variables that point to an underlying type-1 BrP among migraineurs, necessitating cautious use of certain anti-migraine drugs.
INTRODUCTION: We have previously reported high 1-year prevalence of migraine in patients with atrial arrhythmias associated with DI-type 1 BrP. The present study was designed to determine the lifetime prevalence of migraine in patients with Brugada syndrome (BrS) or drug-induced type 1 Brugada pattern (DI-type 1 BrP) and control group, to investigate the demographic and clinical characteristics, and to identify clinical variables to predict underlying BrS/DI-type 1 BrP among migraineurs. METHODS AND RESULTS: Lifetime prevalence of migraine and migraine characteristics were compared between probands with BrS/DI-type 1 BrP (n = 257) and control group (n = 370). Lifetime prevalence of migraine was 60.7% in patients with BrS/DI-type 1 BrP and 30.3% in control group (p = 3.6 × 10-14 ). On stepwise regression analysis, familial migraine (odds ratio [OR] of 4.4; 95% confidence interval [CI]: 2.0-9.8; p = 1.3 × 10-4 ), vestibular migraine (OR of 5.4; 95% CI: 1.4-21.0); p = .013), migraine with visual aura (OR of 1.8; 95% CI: 1.0-3.4); p = .04) and younger age-at-onset of migraine (OR of 0.95; 95% CI: 0.93-0.98); p = .004) were predictors of underlying BrS/DI-type 1 BrP among migraineurs. Use of anti-migraine drugs classified as "to be avoided" or "preferably avoided" in patients with BrS and several other anti-migraine drugs with potential cardiac INa /ICa channel blocking properties was present in 25.6% and 26.9% of migraineurs with BrS/DI-type 1 BrP, respectively. CONCLUSION:Migraine comorbidity is common in patients with BrS/DI-type 1 BrP. We identify several clinical variables that point to an underlying type-1 BrP among migraineurs, necessitating cautious use of certain anti-migraine drugs.
Authors: Charles Antzelevitch; Guido D Pollevick; Jonathan M Cordeiro; Oscar Casis; Michael C Sanguinetti; Yoshiyasu Aizawa; Alejandra Guerchicoff; Ryan Pfeiffer; Antonio Oliva; Bernd Wollnik; Philip Gelber; Elias P Bonaros; Elena Burashnikov; Yuesheng Wu; John D Sargent; Stefan Schickel; Ralf Oberheiden; Atul Bhatia; Li-Fern Hsu; Michel Haïssaguerre; Rainer Schimpf; Martin Borggrefe; Christian Wolpert Journal: Circulation Date: 2007-01-15 Impact factor: 29.690
Authors: Mona Ameri Chalmer; Thomas Folkmann Hansen; Elena R Lebedeva; David W Dodick; Richard B Lipton; Jes Olesen Journal: Cephalalgia Date: 2019-09-22 Impact factor: 6.292
Authors: Pieter G Postema; Christian Wolpert; Ahmad S Amin; Vincent Probst; Martin Borggrefe; Dan M Roden; Silvia G Priori; Hanno L Tan; Masayasu Hiraoka; Josep Brugada; Arthur A M Wilde Journal: Heart Rhythm Date: 2009-07-08 Impact factor: 6.343
Authors: Padhraig Gormley; Verneri Anttila; Bendik S Winsvold; Priit Palta; Tonu Esko; Tune H Pers; Kai-How Farh; Ester Cuenca-Leon; Mikko Muona; Nicholas A Furlotte; Tobias Kurth; Andres Ingason; George McMahon; Lannie Ligthart; Gisela M Terwindt; Mikko Kallela; Tobias M Freilinger; Caroline Ran; Scott G Gordon; Anine H Stam; Stacy Steinberg; Guntram Borck; Markku Koiranen; Lydia Quaye; Hieab H H Adams; Terho Lehtimäki; Antti-Pekka Sarin; Juho Wedenoja; David A Hinds; Julie E Buring; Markus Schürks; Paul M Ridker; Maria Gudlaug Hrafnsdottir; Hreinn Stefansson; Susan M Ring; Jouke-Jan Hottenga; Brenda W J H Penninx; Markus Färkkilä; Ville Artto; Mari Kaunisto; Salli Vepsäläinen; Rainer Malik; Andrew C Heath; Pamela A F Madden; Nicholas G Martin; Grant W Montgomery; Mitja I Kurki; Mart Kals; Reedik Mägi; Kalle Pärn; Eija Hämäläinen; Hailiang Huang; Andrea E Byrnes; Lude Franke; Jie Huang; Evie Stergiakouli; Phil H Lee; Cynthia Sandor; Caleb Webber; Zameel Cader; Bertram Muller-Myhsok; Stefan Schreiber; Thomas Meitinger; Johan G Eriksson; Veikko Salomaa; Kauko Heikkilä; Elizabeth Loehrer; Andre G Uitterlinden; Albert Hofman; Cornelia M van Duijn; Lynn Cherkas; Linda M Pedersen; Audun Stubhaug; Christopher S Nielsen; Minna Männikkö; Evelin Mihailov; Lili Milani; Hartmut Göbel; Ann-Louise Esserlind; Anne Francke Christensen; Thomas Folkmann Hansen; Thomas Werge; Jaakko Kaprio; Arpo J Aromaa; Olli Raitakari; M Arfan Ikram; Tim Spector; Marjo-Riitta Järvelin; Andres Metspalu; Christian Kubisch; David P Strachan; Michel D Ferrari; Andrea C Belin; Martin Dichgans; Maija Wessman; Arn M J M van den Maagdenberg; John-Anker Zwart; Dorret I Boomsma; George Davey Smith; Kari Stefansson; Nicholas Eriksson; Mark J Daly; Benjamin M Neale; Jes Olesen; Daniel I Chasman; Dale R Nyholt; Aarno Palotie Journal: Nat Genet Date: 2016-06-20 Impact factor: 38.330
Authors: Péter Ferdinandy; István Baczkó; Péter Bencsik; Zoltán Giricz; Anikó Görbe; Pál Pacher; Zoltán V Varga; András Varró; Rainer Schulz Journal: Eur Heart J Date: 2019-06-07 Impact factor: 29.983
Authors: Connie R Bezzina; Julien Barc; Yuka Mizusawa; Carol Ann Remme; Jean-Baptiste Gourraud; Floriane Simonet; Arie O Verkerk; Peter J Schwartz; Lia Crotti; Federica Dagradi; Pascale Guicheney; Véronique Fressart; Antoine Leenhardt; Charles Antzelevitch; Susan Bartkowiak; Martin Borggrefe; Rainer Schimpf; Eric Schulze-Bahr; Sven Zumhagen; Elijah R Behr; Rachel Bastiaenen; Jacob Tfelt-Hansen; Morten Salling Olesen; Stefan Kääb; Britt M Beckmann; Peter Weeke; Hiroshi Watanabe; Naoto Endo; Tohru Minamino; Minoru Horie; Seiko Ohno; Kanae Hasegawa; Naomasa Makita; Akihiko Nogami; Wataru Shimizu; Takeshi Aiba; Philippe Froguel; Beverley Balkau; Olivier Lantieri; Margherita Torchio; Cornelia Wiese; David Weber; Rianne Wolswinkel; Ruben Coronel; Bas J Boukens; Stéphane Bézieau; Eric Charpentier; Stéphanie Chatel; Aurore Despres; Françoise Gros; Florence Kyndt; Simon Lecointe; Pierre Lindenbaum; Vincent Portero; Jade Violleau; Manfred Gessler; Hanno L Tan; Dan M Roden; Vincent M Christoffels; Hervé Le Marec; Arthur A Wilde; Vincent Probst; Jean-Jacques Schott; Christian Dina; Richard Redon Journal: Nat Genet Date: 2013-07-21 Impact factor: 38.330
Authors: Anil S Sarica; Serhat Bor; Mehmet N Orman; Hector Barajas-Martinez; Jyh-Ming Jimmy Juang; Charles Antzelevitch; Can Hasdemir Journal: Am J Cardiol Date: 2021-05-24 Impact factor: 3.133